In our exploration of the N-end rule–based PROTACs for PD treatment, we have selected the amino acid Arg as the degradation signal, which was previously employed in the PROTACs against various cancer drivers (e. g., ERRα, BCR-ABL, etc.). This evidence concerns the gene ABL1 and Parkinson disease.